Anti-Cancer Effects of a New Herbal Medicine PSY by Inhibiting the STAT3 Signaling Pathway in Colorectal Cancer Cells and Its Phytochemical Analysis
Abstract
:1. Introduction
2. Results and Discussion
2.1. PSY Synergistically Suppresses Cell Viability in Human CRC Cells
2.2. PSY Induces Cell Cycle Arrest in the G2/M Phase and Apoptosis in Human CRC Cells
2.3. PSY Inhibits the STAT3 Pathway in Human CRC Cells
2.4. Chemical Identification in PSY Extracts
Peak No. | Name | Formula | Mass (Da) | Expected RT (min) | Adduct | Detected at Mass (Da) | Error (ppm) | Fragment Ions (MS/MS Product Ions) | Identified with | Chemical Class |
---|---|---|---|---|---|---|---|---|---|---|
1 | Sucrose | C12H22O11 | 342.1162 | 0.9 | [M−H] – | 341.1091 | 0.3 | 89.0258, 179.0565, 119.0359, 59.0166, 71.0166, 113.0253 | # GNP | Carbohydrate |
2 | Quinic acid | C7H12O6 | 192.0634 | 0.9 | [M−H] – | 191.0567 | 0.8 | 85.0315, 93.0362 | # in-house & GNP | Quinic acid derivatives |
3 | Neochlorogenic acid (3-O-caffeoylquinic acid; 3-CQA) | C16H18O9 | 354.0951 | 4.5 | [M+H] + | 355.1021 | −0.6 | 163.0373, 145.0284, 135.0438, 117.0326 | † | Quinic acid derivatives |
[M−H] – | 353.0877 | −0.3 | 191.0564, 179.0345, 135.0462, 134.0372 | Quinic acid derivatives | ||||||
4 | Loganic acid | C16H24O10 | 376.1370 | 6.6 | [M−H] − | 375.1287 | −1.7 | 213.0762, 169.0864, 151. 0757, 113.0243, 69.0369 | † | Iridoids |
5 | Chlorogenic acid (5-O-caffeoylquinic acid; 5-CQA) | C16H18O9 | 354.0951 | 7.3 | [M+H] + | 355.1025 | 0.3 | 163.0388, 145.0283, 135.0439, 117.0333 | † | Quinic acid derivatives |
[M−H] – | 353.0871 | −2.1 | 191.0566, 161.0252, 173.0464 | Quinic acid derivatives | ||||||
6 | Cryptochlorogenic acid (4-O-caffeoylquinic acid; 4-CQA) | C16H18O9 | 354.0951 | 7.9 | [M+H] + | 355.1024 | 0.2 | 163.0390, 145.0284, 135.0442, 117.0343 | † | Quinic acid derivatives |
[M−H] – | 353.0874 | −1.1 | 191.0557, 173.0449, 135.0451, 179.0350 | Quinic acid derivatives | ||||||
7 | Geniposide | C17H24O10 | 388.1370 | 9.7 | [M−H+FA] – | 433.1341 | 0.2 | 225.0772, 387.1270, 101.0255, 123.0455 | # GNP | Iridoids |
8 | Loganin | C17H26O10 | 390.1526 | 10.2 | [M−H+FA] – | 435.1498 | 0.3 | 227.0929, 127.0414, 101.0264, 389.1474 | † | Iridoids |
9 | Deoxyloganic acid (7- or 8-epi) | C16H24O9 | 360.1420 | 11.1 | [M−H] – | 359.1344 | −2.0 | 197.0823, 135.0823, 153.0915 | # FooDB, GNP & Ref. [21] | Iridoids |
10 | Patrinalloside | C21H34O11 | 462.2101 | 11.6 | [M−H+FA] – | 507.2070 | −0.9 | 361.1498, 403.1605, 343.1391, 161.0449 | Refs. [25,26] | Iridoids |
11 | Deoxyloganic acid (7- or 8-epi) | C16H24O9 | 360.1420 | 12.9 | [M−H] – | 359.1344 | −1.1 | 197.0818, 135.0817, 153.0916,59.0167 | # FooDB, GNP & Ref. [21] | Iridoids |
12 | Eleutheroside E | C34H46O18 | 742.2684 | 13.4 | [M−H+FA] – | 787.2670 | 1.8 | 579.2089, 417.1554, 181.0506 | # GNP | lignans |
13 | Patrinoside/isomers | C21H34O11 | 462.2101 | 13.8 | [M−H+FA] – | 507.2070 | −0.4 | 179.0564, 89.0260, 119.0356, 161.0459, 377.1444 | Refs. [23,24] | Iridoids |
14 | Patrinoside/isomers | C21H34O11 | 462.2101 | 14.3 | [M−H+FA] – | 507.2070 | −0.1 | 179.0559, 461.2007, 89.0262, 377.1447, 119.0358, 161.0457 | Refs. [23,24] | Iridoids |
15 | 1,4-Dicaffeoylquinic acid | C25H24O12 | 516.1268 | 14.9 | [M+H] + | 517.1316 | −2.4 | 163.0377, 145.0273, 499.1216, 319.0789 | † | Quinic acid derivatives |
[M−H] – | 515.1183 | −2.3 | 353.0869, 179.0340, 173.0452, 191.0553 | |||||||
16 | 1,3-Dicaffeoylquinic acid | C25H24O12 | 516.1268 | 15.2 | [M+H] + | 517.1332 | −1.7 | 163.0391, 145.0294, 135.0431, 117.0331 | † | Quinic acid derivatives |
[M−H] – | 515.1188 | −1.4 | 353.0866, 191.0556, 179.0338, 135.0455 | |||||||
17 | 4,5-Dicaffeoyl quinic acid | C25H24O12 | 516.1268 | 15.9 | [M+H] + | 517.1338 | −0.6 | 163.0382, 145.0260, 135.0421,337.0906 | † | Quinic acid derivatives |
[M−H] – | 515.1191 | −0.8 | 353.0874, 173.0454, 179.0346, 191.0556 | |||||||
18 | Nortrachelogenin | C20H22O7 | 374.1366 | 17.1 | [M−H] – | 373.1291 | −0.5 | 179.0714, 164.0476, 99.0099, 327.1238, 163.0476 | # GNP | lignans |
19 | Kuwanon L | C35H30O11 | 626.1788 | 19.7 | [M+H] + | 627.1853 | −1.2 | 309.1740, 153.0181, 137.0233, 433.0908, 499.1374 | * | Diels-Alder (DA)-type flavonoids |
[M−H] – | 625.1716 | 0.1 | 499.1406, 389.1025, 125.0253, 109.0306 | |||||||
20 | Kuwanon Y | C34H30O9 | 582.1890 | 19.8 | [M+H] + | 583.1947 | −2.6 | 203.0706, 137.0237, 339.1218, 473.1585 | # FooDB | Diels-Alder (DA)-type flavonoids |
[M−H] – | 581.1813 | −0.6 | 361.1089, 471.1463, 227.0716, 243.0666, 563.1738 | |||||||
21 | Mulberrofuran G | C34H26O8 | 562.1628 | 20.2 | [M+H] + | 563.1695 | −0.9 | 441.1345, 255.0661, 123.0449, 387.0873 | * | Diels-Alder (DA)-type flavonoids |
[M−H] – | 561.1540 | −1.1 | 451.12190, 439.1187, 433.1072, 241.0508 | * | ||||||
22 | Sangenon F/isomers | C20H18O6 | 354.1103 | 20.6 | [M+H] + | 355.1178 | 0.4 | 153.0189 | * | Prenylflavonoids |
[M−H] – | 353.1027 | −1.0 | 227.0712, 125.0251, 201.0920 | |||||||
23 | Kuwanon G | C40H36O11 | 692.2258 | 21.4 | [M+H] + | 693.2321 | −1.4 | 137.0235, 203.0708, 365.1026, 299.0556, 421.1654 | † | Diels-Alder (DA)-type flavonoids |
[M−H] – | 691.2182 | −1.0 | 581.1820, 353.1029, 419.1501, 379.1189, 539.1719 | |||||||
22-1 | Sangenon F/ isomers | C20H18O6 | 354.1103 | 21.5 | [M+H] + | 355.1178 | 0.7 | 153.0184 | * | Prenylflavonoids |
[M−H] – | 353.1027 | −0.8 | 125.0257, 201.0927, 227.0712 | |||||||
24 | Kuwanon O or Sanggenon G/isomers | C40H38O11 | 694.2374 | 22.1 | [M+H] + | 695.2452 | −2.2 | 205.0858, 341.1381, 267.0650, 677.2367 | Ref. [29] | Diels-Alder (DA)-type flavonoids |
694.2433 | 22.1 | [M−H] – | 693.2350 | −0.7 | 567.2098, 389.1034, 177.0919, 125.0243 | |||||
25 | Kuwanon C | C25H26O6 | 422.1729 | 22.8 | [M+H] + | 423.1802 | −1.8 | 311.0549, 241.0494, 283.0599, 367.1179 | # GNP | Prenylflavonoids |
[M−H] – | 421.1654 | −0.7 | 299.1292, 309.0411, 193.0870, 219.0667, 297.0408 | |||||||
26 | Kuwanon O/isomer | C40H38O11 | 694.2374 | 23.1 | [M+H] + | 695.2452 | 0.7 | 271.1323, 137.0234, 407.1849, 297.1482 | * | Diels-Alder (DA)-type flavonoids |
694.2433 | 23.1 | [M−H] – | 693.2350 | −1.5 | 531.2031, 287.0563, 259.1341, 125.0253, 583.1993 | * | ||||
27 | 13-keto-9Z,11E-octadecadienoic acid | C18H30O3 | 294.2195 | 24.1 | [M−H] – | 293.2120 | −0.6 | 275.2007, 235.1692, 183.1383, 171.1018 | * | Fatty acids |
28 | Kuwanon E | C25H28O6 | 424.1886 | 25.7 | [M+H] + | 425.1955 | −0.8 | 153.0183, 175.3939 | # FooDB | Prenylflavonoids |
[M−H] – | 423.1806 | −1.7 | 297.1492, 125.0250, 271.1705, 177.0195, 245.1545, 405.1703 | |||||||
29 | 13-Hydroxyoctadecadienoic acid | C18H32O3 | 296.2352 | 26.0 | [M−H] – | 295.2272 | 0.0 | 277.2181, 195.1392, 171.1033 | * | Fatty acids |
30 | Kuwanon T | C25H26O6 | 422.1729 | 26.2 | [M+H] + | 423.1796 | −1.5 | 153.0178, 175.0385 | * | Prenylflavonoids |
[M−H] – | 421.1657 | 0.1 | 295.1341, 125.0252, 269.1550, 174.0329, 151.0040 | |||||||
31 | Morusin | C25H24O6 | 420.1573 | 27.0 | [M+H] + | 421.1645 | −0.3 | 365.1012, 347.0913, 332.0682, 295.0953 | † | Prenylflavonoids |
27.0 | [M−H] – | 419.1501 | 0.2 | 297.1134, 191.0716, 309.1139, 350.04804, 217.0507 | ||||||
32 | Linolenic acid | C18H30O2 | 278.2246 | 29.2 | [M−H] – | 277.2175 | 0.8 | 277.2175 | # GNP | Fatty acids |
33 | Oleamide | C18H35NO | 281.2719 | 29.8 | [M+H] + | 282.2794 | 0.9 | 247.2419, 265.2525, 97.1019, 135.1168, 121.1013,149.1321 | # GNP | Fatty acid amide |
34 | Linoleic acid | C18H32O2 | 280.2402 | 29.9 | [M−H] – | 279.2335 | 1.9 | 279.2335 | † | Fatty acids |
35 | 3-Oxo-olean-12-en-28-oic acid | C30H46O3 | 454.3447 | 30.4 | [M−H] – | 453.3365 | −2.1 | 453.3365 | † | Fatty acids |
36 | Palmitic acid | C16H32O2 | 256.2402 | 30.5 | [M−H] – | 255.2329 | −0.4 | 255.2329 | † | Fatty acids |
37 | Oleic acid | C18H34O2 | 282.2559 | 31.7 | [M−H] – | 281.2485 | −0.6 | 283.2643 | † | Fatty acids |
2.5. Identification of Potential Bioactive Phytochemicals in PSY EtOH-Ex
3. Materials and Methods
3.1. PSY Preparation
3.2. Chemicals and Reagents
3.3. Cell Lines and Culture Condition
3.4. Cell Viability Assays
3.5. Cell Cycle Analysis
3.6. Apoptosis Analysis
3.7. Immunofluorescence Staining
3.8. Transient Transfection and Luciferase (Luc) Assays
3.9. Western Blotting Analysis
3.10. Ultra-Performance Liquid Chromatography Quadrupole Time of Flight Mass Spectrophotometry (UPLC-ESI-QTOF MS/MS) Analysis
3.11. Phytochemical Identification in PSY
3.12. Statistical Analysis
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Clinton, S.K.; Giovannucci, E.L.; Hursting, S.D. The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions. J. Nutr. 2020, 150, 663–671. [Google Scholar] [CrossRef] [PubMed]
- Terzic, J.; Grivennikov, S.; Karin, E.; Karin, M. Inflammation and colon cancer. Gastroenterology 2010, 138, 2101–2114.e5. [Google Scholar] [CrossRef] [PubMed]
- Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 2009, 9, 798–809. [Google Scholar] [CrossRef]
- Chalikonda, G.; Lee, H.; Sheik, A.; Huh, Y.S. Targeting key transcriptional factor STAT3 in colorectal cancer. Mol. Cell. Biochem. 2021, 476, 3219–3228. [Google Scholar] [CrossRef]
- Zhang, Z.H.; Li, M.Y.; Wang, Z.; Zuo, H.X.; Wang, J.Y.; Xing, Y.; Jin, C.; Xu, G.; Piao, L.; Piao, H.; et al. Convallatoxin promotes apoptosis and inhibits proliferation and angiogenesis through crosstalk between JAK2/STAT3 (T705) and mTOR/STAT3 (S727) signaling pathways in colorectal cancer. Phytomedicine 2020, 68, 153172. [Google Scholar] [CrossRef]
- Huehnchen, P.; van Kampen, A.; Boehmerle, W.; Endres, M. Cognitive impairment after cytotoxic chemotherapy. Neurooncol. Pract. 2020, 7, 11–21. [Google Scholar] [CrossRef] [Green Version]
- Tofthagen, C. Surviving chemotherapy for colon cancer and living with the consequences. J. Palliat. Med. 2010, 13, 1389–1391. [Google Scholar] [CrossRef]
- Guldiken, B.; Ozkan, G.; Catalkaya, G.; Ceylan, F.D.; Ekin Yalcinkaya, I.; Capanoglu, E. Phytochemicals of herbs and spices: Health versus toxicological effects. Food Chem. Toxicol. 2018, 119, 37–49. [Google Scholar] [CrossRef]
- Heo, J. DONGUIBOGAM Treasured Mirror of Eastern Medicine; Bubin Publishers Co.: Seoul, Republic of Korea, 2005. [Google Scholar]
- Huang, S.Z.; Liu, W.Y.; Huang, Y.; Shen, A.L.; Liu, L.Y.; Peng, J. Patrinia scabiosaefolia Inhibits Growth of 5-FU-Resistant Colorectal Carcinoma Cells via Induction of Apoptosis and Suppression of AKT Pathway. Chin. J. Integr. Med. 2019, 25, 116–121. [Google Scholar] [CrossRef]
- Liu, L.; Shen, A.; Chen, Y.; Wei, L.; Lin, J.; Sferra, T.J.; Hong, Z.; Peng, J. Patrinia scabiosaefolia induces mitochondrial-dependent apoptosis in a mouse model of colorectal cancer. Oncol. Rep. 2013, 30, 897–903. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, M.Y.; Lin, H.Y.; Cheng, F.; Chiang, W.; Kuo, Y.H. Isolation and characterization of new lactam compounds that inhibit lung and colon cancer cells from adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) bran. Food Chem. Toxicol. 2008, 46, 1933–1939. [Google Scholar] [CrossRef]
- Son, E.S.; Kim, Y.O.; Park, C.G.; Park, K.H.; Jeong, S.H.; Park, J.W.; Kim, S.H. Coix lacryma-jobi var. ma-yuen Stapf sprout extract has anti-metastatic activity in colon cancer cells in vitro. BMC Complement. Altern. Med. 2017, 17, 486. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eo, H.J.; Park, J.H.; Park, G.H.; Lee, M.H.; Lee, J.R.; Koo, J.S.; Jeong, J.B. Anti-inflammatory and anti-cancer activity of mulberry (Morus alba L.) root bark. BMC Complement. Altern. Med. 2014, 14, 200. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Park, H.J.; Park, S.H. Root Bark of Morus Alba L. Induced p53-Independent Apoptosis in Human Colorectal Cancer Cells by Suppression of STAT3 Activity. Nutr. Cancer 2022, 74, 1837–1848. [Google Scholar] [CrossRef]
- Li, B.; Tao, W.; Zheng, C.; Shar, P.A.; Huang, C.; Fu, Y.; Wang, Y. Systems pharmacology-based approach for dissecting the addition and subtraction theory of traditional Chinese medicine: An example using Xiao-Chaihu-Decoction and Da-Chaihu-Decoction. Comput. Biol. Med. 2014, 53, 19–29. [Google Scholar] [CrossRef]
- Huynh, J.; Chand, A.; Gough, D.; Ernst, M. Therapeutically exploiting STAT3 activity in cancer—Using tissue repair as a road map. Nat. Rev. Cancer 2019, 19, 82–96. [Google Scholar] [CrossRef]
- Morikawa, T.; Baba, Y.; Yamauchi, M.; Kuchiba, A.; Nosho, K.; Shima, K.; Tanaka, N.; Huttenhower, C.; Frank, D.A.; Fuchs, C.S.; et al. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin. Cancer Res. 2011, 17, 1452–1462. [Google Scholar] [CrossRef] [Green Version]
- Peng, J.; Chen, Y.; Lin, J.; Zhuang, Q.; Xu, W.; Hong, Z.; Sferra, T.J. Patrinia scabiosaefolia extract suppresses proliferation and promotes apoptosis by inhibiting the STAT3 pathway in human multiple myeloma cells. Mol. Med. Rep. 2011, 4, 313–318. [Google Scholar]
- Zhong, Y.-M.; Zhong, X.-L.; Wang, J.-H.; Han, L. Rapid analysis and identification of the main constituents in Patrinia scabiosaefolia Fisch. by UPLC/Q-TOF-MS/MS. Acta Chromatogr. 2017, 29, 267–277. [Google Scholar] [CrossRef] [Green Version]
- Gong, L.; Zou, W.; Zheng, K.; Shi, B.; Liu, M. The Herba Patriniae (Caprifoliaceae): A review on traditional uses, phytochemistry, pharmacology and quality control. J. Ethnopharmacol. 2021, 265, 113264. [Google Scholar] [CrossRef]
- Taguchi, H.; Endo, T. Letter: Patrinoside, a new iridoid glycoside from Patrinia scabiosaefolia. Chem. Pharm. Bull. 1974, 22, 1935–1937. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Taguchi, H.; Endo, T.; Yosioka, I.; Iitaka, Y. The revised stereostructure of patrinoside X-ray crystallographic analysis. Chem. Pharm. Bull. 1979, 27, 1275–1276. [Google Scholar] [CrossRef] [Green Version]
- Kim, J.S.; Kang, S.S. Chemical constituents of plants from the genus Patrinia. Nat. Prod. Sci. 2013, 19, 77–119. [Google Scholar]
- Huang, L.; Zhang, R.S.; Wang, C.F.; Zhang, S.F. Studies on chemical constituents of Patrinia villosa. Zhong Yao Cai 2007, 30, 415–417. [Google Scholar]
- Choi, E.J.; Shin, J.E.; Kim, H.G.; Kim, J.J.; Woo, E.-R. Lignans Isolated from the Roots of Patrinia scabiosaefolia F. and their IL(Interleukin)-6 Inhibitory Activity. Yakhak Hoeji 2009, 53, 201–205. [Google Scholar]
- Park, D.; Ha, I.J.; Park, S.Y.; Choi, M.; Lim, S.L.; Kim, S.H.; Lee, J.H.; Ahn, K.S.; Yun, M.; Lee, S.G. Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells. J. Nat. Prod. 2016, 79, 317–323. [Google Scholar] [CrossRef]
- Jing, W.; Yan, R.; Wang, Y. A practical strategy for chemical profiling of herbal medicines using ultra-high performance liquid chromatography coupled with hybrid triple quadrupole-linear ion trap mass spectrometry: A case study of Mori Cortex. Anal. Methods 2015, 7, 443–457. [Google Scholar] [CrossRef]
- Shi, X.; Mackie, B.; Zhang, G.; Yang, S.; Song, Y.; Su, D.; Liu, Y.; Shan, L. Identification of the Metabolic Enzyme Involved Morusin Metabolism and Characterization of Its Metabolites by Ultraperformance Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (UPLC/Q-TOF-MS/MS). Evid. Based Complement. Altern. Med. 2016, 2016, 9240103. [Google Scholar] [CrossRef] [Green Version]
- Lim, S.-L.; Park, S.-Y.; Kang, S.; Park, D.; Kim, S.-H.; Um, J.-Y.; Jang, H.-J.; Lee, J.-H.; Jeong, C.-H.; Jang, J.-H.; et al. Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells. Am. J. Cancer Res. 2015, 5, 289–299. [Google Scholar]
- Choi, D.W.; Cho, S.W.; Lee, S.G.; Choi, C.Y. The Beneficial Effects of Morusin, an Isoprene Flavonoid Isolated from the Root Bark of Morus. Int. J. Mol. Sci 2020, 21, 6541. [Google Scholar] [CrossRef]
- Guo, H.; Xu, Y.; Huang, W.; Zhou, H.; Zheng, Z.; Zhao, Y.; He, B.; Zhu, T.; Tang, S.; Zhu, Q. Kuwanon G Preserves LPS-Induced Disruption of Gut Epithelial Barrier In Vitro. Molecules 2016, 21, 1597. [Google Scholar] [CrossRef] [Green Version]
- Numata, M.; Yamamoto, A.; Moribayashi, A.; Yamada, H. Antitumor components isolated from the Chinese herbal medicine Coix lachryma-jobi. Planta Med. 1994, 60, 356–359. [Google Scholar] [CrossRef] [PubMed]
- Jozwiak, M.; Filipowska, A.; Fiorino, F.; Struga, M. Anticancer activities of fatty acids and their heterocyclic derivatives. Eur. J. Pharm. 2020, 871, 172937. [Google Scholar] [CrossRef] [PubMed]
- Liu, S.; Shen, H.; Li, J.; Gong, Y.; Bao, H.; Zhang, J.; Hu, L.; Wang, Z.; Gong, J. Loganin inhibits macrophage M1 polarization and modulates sirt1/NF-kappaB signaling pathway to attenuate ulcerative colitis. Bioengineered 2020, 11, 628–639. [Google Scholar] [CrossRef] [PubMed]
- Miller, K.D.; Nogueira, L.; Devasia, T.; Mariotto, A.B.; Yabroff, K.R.; Jemal, A.; Kramer, J.; Siegel, R.L. Cancer treatment and survivorship statistics, 2022. CA Cancer J. Clin. 2022, 72, 409–436. [Google Scholar] [CrossRef]
- Hofmann, C.; Buttenschoen, K.; Straeter, J.; Henne-Bruns, D.; Kornmann, M. Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy. Anticancer Res. 2005, 25, 795–804. [Google Scholar]
- Ciardiello, F.; Ciardiello, D.; Martini, G.; Napolitano, S.; Tabernero, J.; Cervantes, A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J. Clin. 2022, 72, 372–401. [Google Scholar] [CrossRef]
- Lee, S.G.; Jeon, H.Y.; Su, Z.Z.; Richards, J.E.; Vozhilla, N.; Sarkar, D.; Van Maerken, T.; Fisher, P.B. Astrocyte elevated gene-1 contributes to the pathogenesis of neuroblastoma. Oncogene 2009, 28, 2476–2484. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Han, S.; Kim, H.; Lee, M.Y.; Lee, J.; Ahn, K.S.; Ha, I.J.; Lee, S.-G. Anti-Cancer Effects of a New Herbal Medicine PSY by Inhibiting the STAT3 Signaling Pathway in Colorectal Cancer Cells and Its Phytochemical Analysis. Int. J. Mol. Sci. 2022, 23, 14826. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232314826
Han S, Kim H, Lee MY, Lee J, Ahn KS, Ha IJ, Lee S-G. Anti-Cancer Effects of a New Herbal Medicine PSY by Inhibiting the STAT3 Signaling Pathway in Colorectal Cancer Cells and Its Phytochemical Analysis. International Journal of Molecular Sciences. 2022; 23(23):14826. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232314826
Chicago/Turabian StyleHan, Sanghee, Hail Kim, Min Young Lee, Junhee Lee, Kwang Seok Ahn, In Jin Ha, and Seok-Geun Lee. 2022. "Anti-Cancer Effects of a New Herbal Medicine PSY by Inhibiting the STAT3 Signaling Pathway in Colorectal Cancer Cells and Its Phytochemical Analysis" International Journal of Molecular Sciences 23, no. 23: 14826. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232314826